Dear Editor,

As reviewed by Cao et al., the availability of results of previous research studies helped in prioritizing clinical trials for Remdesivir \[[@bib1]\]. The molecule was covered in WHO\'s Director General\'s opening remarks on February 20, 2020 and is also included in Solidarity Clinical Trial for COVID-19 Treatments \[[@bib2]\]. However, due to lack of published results or papers, the panel expressed indecisiveness for prioritization of Favipiravir (Favilavir), which was discovered much earlier than Remdesivir. Since discovery and development of newer drugs take long time, reviewing therapeutic evidence on safety and efficacy of existing drugs and expediting approval of suitable candidates is crucial for quickly providing effective therapeutics to save lives amidst ongoing pandemics like COVID-19, which has resulted in 2,096,573 confirmed cases with around 135,662 deaths globally (as on 16 April 2020). Table 1Favipiravir past Clinical trials & results availability in the clinical trial registry portals:Table 1S·NOClinical TrialTarget Population/ IndicationCurrent StatusAvailability of Result1JapicCTI-142657 (Phase I)Healthy VolunteersCompleted***Not available***2NCT01419457 (Phase I)Volunteers with mild to severe hepatic impairmentCompleted***Not available***3NCT01728753 (Phase I)Mild to severe InfluenzaCompleted***Not available***4NCT01068912 (Phase II)Moderate to severe InfluenzaCompletedAvailable5NCT03394209 (Phase II)Combined Favipiravir and Oseltamivir regimen in InfluenzaCompleted***Not available***6NCT02026349 (Phase III)InfluenzaCompletedAvailable7NCT02008344 (Phase III)InfluenzaCompleted***Not available***8UMIN000016101Ebola in adultsCompleted***Not available***9NCT02329054 (Phase II)Ebola in all age groupsCompleted***Not available***10NCT02662855 (Phase II)Severe Ebola Disease in adultsCompleted***Not available***11UMIN000016102Prevention of Ebola in exposed adultsCompleted***Not available***12UMIN000022398Severe fever with thrombocytopeniaCompleted***Not available***13UMIN000029020Severe fever with thrombocytopeniaCompleted***Not available***14JapicCTI-183872 (Phase III)Severe fever with thrombocytopeniaCompleted***Not available***15ChiCTR2000030113COVID-19 patients with poor response to RitonavirOngoing***Not available***16ChiCTR2000029600COVID-19 PneumoniaOngoing***Not available***17ChiCTR2000029548Comparing Baloxavir Marboxil, Favipiravir, Lopinavir-Ritonavir in COVID-19 PneumoniaOngoing***Not available***18ChiCTR2000029544Comparing Baloxavir Marboxil and Favipiravir in COVID-19 positive patients despite antiviralsOngoing***Not available***

Favipiravir, a pyrazine carboxamide derivative, is a novel broad-spectrum antiviral drug originally developed many years ago for influenza. It selectively inhibits the influenza viral RNA-dependent RNA polymerase, thereby blocking the process of replication by negatively acting on genetic copying. Due to its activity against RNA viruses, it has been tested against several RNA viruses including H1N1, Ebola, Arena virus, and Bunyavirus. However, it was approved for a few indications in Japan and France and not in other countries.

To assess suitability of Favipravir for repurposing in COVID-19, we conducted a mini-review of clinical trials using Favipiravir as an investigational drug for various indications in all 18 primary clinical trial registries in the WHO Registry Network and identified 19 such trials. These trials are summarized below.

Out of 19 Favipiravir trials identified, one dose-escalation trial on Ebola patients (NCT02739477) was terminated due to the end date of the epidemic. Out of remaining 18 trials, fourteen have been completed and four trials on COVID-19 are ongoing in China (see [Table 1](#tbl1){ref-type="table"}). Results of only two trials have been published in registries and remaining 12 trials results could not be retrieved from repositories. Study results posted for a multi-centric phase II trial (NCT01068912) \[[@bib3]\] demonstrated clinical efficacy of Favipiravir in Influenza, in low-dose as well as high-dose regimens, with no mortality, and no major risk of serious adverse events. Study results for multi-centric phase III trial (NCT02026349) \[[@bib4]\] posted on EudraCT revealed that Favipiravir could alleviate symptoms and resolve fever in Influenza without any mortality or serious adverse event. Results of the rest of the 12 completed trials were not available in the registries at the time of writing this article.

It is evident that Favipiravir could result in positive therapeutic outcomes in Influenza. Unavailability of results from \>85% of favipiravir completed clinical trials in registries or in published papers prevented pooling of data and conducting meta-analysis to generate conclusive evidence to support recommendation of Favipiravir use in COVID-19 or know about its safety and efficacy profile.

Many such promising drugs can be overlooked by scientific panels due to lack of conclusive evidence, especially when expedited repurposing and approval of therapeutics effective in pandemic is needed. We might already have available drugs with significant potential to curb the spread of new Coronavirus and prevent significant morbidity and mortality. The authors conclude that reporting of all available results and evidence from past clinical trials, even if it indicates failure of interventions evaluated, must be ensured for enabling timely repurposing of effective therapeutics based on scientific evidence from past. Absence of published results from past clinical trials not only hinders future evidence-based research but also may violate data transparency norms set by several countries and undermine ethical standards overall. Through this mini review evaluating prior and ongoing clinical trials on Favipiravir, it is urged that the findings of these trials be made available and disseminated to the scientific community so that it may facilitate timely and crucial understanding of Favipiravir as a potential therapeutic option during COVID-19 pandemic.
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